ArticleClinical drug investigation2026
Urinary MicroRNA Expression and Tacrolimus Pharmacokinetic Variability in Kidney Transplant Recipients: A Cross-sectional Study.
Article in Clinical drug investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundDysregulation of specific microRNAs and the intraindividual (IPV) and interindividual pharmacokinetic variability of tacrolimus (Tac) have been associated with unfavorable long-term outcomes after kidney transplantation. It remains unknown whether the effects of Tac pharmacokinetic variability are reflected in microRNA expression.
objectiveThe primary objective was to analyze the correlation between urinary microRNA (miR-21-5p, miR-142-3p, miR-155-5p, and miR-204-5p) relative expression levels in the long term and Tac pharmacokinetic variability parameters within the early period after kidney transplantation. Secondarily, correlation between urinary microRNA expression and long-term graft function were analyzed.
methodsIn a cross-sectional study, the urinary microRNA expression levels were determined in 50 kidney transplant recipients in the long-term period after kidney transplantation and in 12 healthy controls. Patients were divided based on the Tac IPV and metabolic phenotype, defined by Tac dose-adjusted concentration (C
resultsUrinary expression of miR-142-3p (p = 0.022) and miR-204-5p (p = 0.007), but not miR-21-5p and miR-155-5p, differed significantly between patients in the long-term post-transplantation period and healthy controls. Patients characterized by fast/intermediate Tac metabolic phenotype had decreased urinary miR-204-5p expression compared to slow metabolizers (p = 0.007; p = 0.005, respectively). Patients with estimated glomerular filtration rate (eGFR) ≥ 45 mL/min/1.73 m
conclusionThis study indicated that the urinary expression levels of miR-142-3p and miR-204-5p were significantly different between kidney transplant recipients and healthy controls. Additionally, urinary miR-204-5p expression may be correlated with graft function in the long‑term post‑transplantation period, as well as with early Tac C
Indexed as
Identifiers
41904367What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.